Browse News

Found 91 articles

• Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board

  12/4/2023

  Nanoscope Therapeutics today announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately.

• Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress

  12/1/2023

  Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Francesco Bandello, MD, FEBO, will present at the 11th Annual FLORetina Congress taking place from November 30 - December 3, 2023 in Rome, Italy.

• Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII

  11/30/2023

  Nanoscope Therapeutics Inc. today announced that Jared Stephens , PhD, Vice President of Strategy and Business Development, will present at the 13th Annual Ophthalmology Innovation Summit (OIS) taking place from December 1-2 in San Diego, California.

• Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit

  11/9/2023

  Nanoscope Therapeutics Inc. announced that Dr. Samarendra Mohanty, President and Chief Scientific Officer will participate in a panel and present at the 4th Annual Dry AMD Therapeutic Development Summit taking place from November 14-16, 2023 in Boston, Massachusetts.

• Nanoscope Therapeutics Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2023

  10/30/2023

  Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced presentations at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting and Eyecelerator @ AAO 2023 taking place in San Francisco, California.

• Nanoscope Therapeutics Strengthens Research and Development Leadership with Appointment of Najam Sharif, PhD, DSc.

  10/26/2023

  Nanoscope Therapeutics Inc. announced the appointment of Najam Sharif, PhD, DSc, a veteran in drug/device discovery and development, as Vice President of Global Research and Development.

• Nanoscope Therapeutics Announces Presentations at The Retina Society 56th Annual Scientific Meeting

  10/9/2023

  Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and macular degenerations, today announced presentations at The Retina Society 56th Annual Scientific Meeting taking place in New York, New York from October 11-14, 2023.

• Nanoscope Therapeutics Announces Presentations in Upcoming October 2023 Conferences

  10/2/2023

  Nanoscope Therapeutics Inc. is scheduled to participate in the 2023 Ophthalmology Futures Retina Forum and Euretina Innovation Spotlight at the 23rd Euretina Congress, each taking place in Amsterdam, The Netherlands.

• Nanoscope Therapeutics to Present at the 4th Annual Gene Therapy for Ophthalmic Disorders Summit

  9/28/2023

  Nanoscope Therapeutics Inc. today announced that Dr. Sam Barone, Chief Medical Officer, will give a presentation on the clinical development of Nanoscope's Multi-Characteristic Opsin (MCO) gene therapy platform at the 4th Annual Gene Therapy for Ophthalmic Disorders Summit taking place from October 3-5 in Boston, Massachusetts.

• Nanoscope Therapeutics Strengthens Clinical and Regulatory Expertise With Appointment of Samuel Barone, M.D., as Chief Medical Officer

  9/21/2023

  Nanoscope Therapeutics Inc. announced the appointment of Samuel Barone, M.D., an accomplished leader in the pharmaceutical space and former FDA official, as Chief Medical Officer.

• Nanoscope Therapeutics Unveils Clinical Trial Results for MCO-010 in Treating Stargardt Disease

  8/9/2023

  Nanoscope Therapeutics Inc. presented key results from its Phase 2 clinical trial, STARLIGHT, at the American Society of Retina Specialists (ASRS) annual meeting in Seattle last week.

• Nanoscope Therapeutics to Present at the 2023 American Society of Retina Specialists (ASRS) Annual Scientific Meeting

  7/21/2023

  Nanoscope Therapeutics Inc. today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in a presentation at the 2023 ASRS Annual Scientific Meeting taking place from July 28-August 1, 2023.

• Nanoscope Therapeutics to Participate in the Baird 2023 Biotech Discovery Series

  6/12/2023

  Nanoscope Therapeutics Inc. today announced that Sulagna Bhattacharya, Co-Founder and Chief Executive Officer, Dr. Samarendra Mohanty, Co-Founder and President, and Dr. Victor Hugo Gonzalez, Valley Retina Institute, will participate in a fireside chat at Baird's Biotech Discovery Series.

• Nanoscope Therapeutics Announces Participation in Upcoming Conferences

  6/8/2023

  Nanoscope Therapeutics Inc. is scheduled to participate in the following conferences.

• Nanoscope Therapeutics to Present at the BIO International Convention

  6/5/2023

  Nanoscope Therapeutics Inc. today announced that management will present at the BIO International Convention, taking place June 5-8, 2023, in Boston, MA.

• Nanoscope Therapeutics Announces Presentations at the World Orphan Drug Congress

  5/22/2023

  Nanoscope Therapeutics Inc. today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in multiple presentations at the World Orphan Drug Congress, taking place May 23-25, 2023.

• Nanoscope Therapeutics Announces Presentations at the 2023 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

  5/11/2023

  Nanoscope Therapeutics Inc. today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in a presentation at the 26th ASGCT Annual Meeting, taking place May 16-20, 2023 in Los Angeles, CA.

• Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual Meeting

  4/27/2023

  Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced the presentation of key data from its Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010 at the ARVO annual meeting.

• Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting

  4/13/2023

  Nanoscope Therapeutics Inc. today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in three presentations at the ARVO Annual Meeting, taking place April 23-27, 2023 in New Orleans.

• Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa

  3/30/2023

  Nanoscope Therapeutics Inc., today announced topline results from the Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772)  of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation.